Restrictive allograft dysfunction after lung transplantation: is there a place for nintedanib?—a case report. (22nd January 2020)

• Record Type: Journal Article
• Authors: Pluchart, Hélène; Chanoine, Sébastien; Briault, Amandine; Claustre, Johanna; Bedouch, Pierrick
• Is Part Of: Fundamental & clinical pharmacology. Volume 34:Number 3(2020)
• Page Start: 408
• Page End: 411
• Publication Date: 2020-01-22
• Subjects: chronic lung allograft dysfunction -- lung transplantation -- restrictive allograft syndrome; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/fcp.12522
• Languages: English
• ISSNs: 0767-3981

Abstract

Abstract: One of the posttransplantation complications is represented by chronic lung allograft dysfunction, which has two main clinical presentations: bronchiolitis obliterans syndrome and restrictive allograft syndrome. The latter being challenging because of poor prognosis and only symptomatic treatment, and characterized by fibrotic process. A 63‐year‐old man was right lung‐transplanted in 2009 due to idiopathic pulmonary fibrosis. In 2011, bronchiolitis obliterans syndrome was diagnosed evolving to restrictive allograft syndrome in 2016. An off‐label treatment by nintedanib (150 mg twice a day) was introduced. Unfortunately, it was stopped 4 months later because of digestive intolerance, without any clinical improvement. Contrary to a previous case reported, our patient did not have any benefit of nintedanib. Antifibrotic agents' effects such as nintedanib on restrictive allograft syndrome should be assessed in further randomized double‐blind placebo‐controlled studies.